PFEPfizerRunning, no new patients
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 257 (final count)
- Started
- Jan 15, 2021
- Main results expected
- Oct 30, 2026
- Fully finished
- Oct 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety Lead In (SLI): Incidence of Dose Limiting Toxicities (DLTs)
Measured over: First 2 Cycles of Treatment (cycles are 21 days)
Phase 3: Objective Response (OR) by Blinded Independent Central Review (BICR)
Measured over: Time from the date of randomization until documented PD, start of subsequent anticancer therapy, or death due to any cause (approximately every 9 weeks).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04657991 · record last updated 2026-09-03 · checked 2026-11-09 15:36 UTC